📊 Research: A Rainbow Behind the Cloud

Plus, a Permian Basin play that just got a 73% PT bump, a GPCR drug developer with 60% upside potential, and more...

Apr 18, 2026

Apr 11, 2026

•

2 min read

Plus, a precision oncology biotech with room to run, a CNS drug challenger with nearly $4B in projected peak sales, and more...

Apr 4, 2026

•

2 min read

Plus, a top-1% analyst's highest-conviction AI infrastructure bet and the post-IPO software name Goldman says the market is missing out on.